Regeneron Pharma (REGN) PT Lowered to $812 at Truist Securities

Truist Securities analyst Srikripa Devarakonda lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $812.00 (from $940.00) while maintaining a Buy rating.

The analyst commented: "2Q25: top & bottom beat. Pipeline and indication expansions continue to deliver value; While near-term investor focus remains on the Eylea tail & Eylea HD uptake, REGN continues to deliver growth on its top/bottom line with Dupi and Libtayo. We see near-term value inflection points with additional launches and label expansions along w/ a robust and maturing pipeline with best-in-class profiles across multiple therapeutic areas with nearterm catalysts that are not yet appreciated by the Street. Given the ongoing competitive pressure and pricing headwinds for Eylea, we model peak Eylea/Eylea HD 2035E sales of $3.2B versus $3.6B consensus. Following COPD Ph3 data, we are also removing credit to itepekimab. Reiterate Buy, new PT $812 vs $940, previously."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
• BorgWarner (BWA) PT Raised to $95 at Wolfe Research, 'Bullish Takeaways from CEO Meetings'